Merad, M <br/><br/>
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)   
 - 369-78 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-9557 
<br/><br/><label>Standard No.: </label>10.1097/00002371-200005000-00010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--immunology<br/>Carcinoma, Renal Cell--immunology<br/>Cytokines--immunology<br/>Dendritic Cells--drug effects<br/>Drug Therapy, Combination<br/>Granulocyte-Macrophage Colony-Stimulating Factor--immunology<br/>Histocompatibility Antigens Class II--immunology<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Interferon-alpha--administration & dosage<br/>Interleukin-12--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Interleukin-4--immunology<br/>Kidney Neoplasms--immunology<br/>Lymphocyte Culture Test, Mixed<br/>Melanoma--immunology<br/>Monocytes--immunology<br/>Neoplasm Metastasis<br/>Peptides--immunology<br/>Recombinant Proteins--therapeutic use<br/>T-Lymphocytes--immunology<br/>Tetanus Toxoid